Giredestrant Promising New Treatment For Early-Stage HR-Positive Breast Cancer
Breastcancer.org PodcastShow Notes
After surgery, many people with stage I to stage III hormone receptor-positive breast cancer take tamoxifen or an aromatase inhibitor for five to 10 years. This has been the standard of care for the last 25 years.
At the 2025 San Antonio Breast Cancer Symposium, UCLA scientist Dr. Aditya Bardia presented results on giredestrant, a new oral selective estrogen degrader/downregulator (SERD) that offered better disease-free survival — how long people live without the cancer returning – than tamoxifen or an aromatase inhibitor.
Listen to the episode to hear Dr. Bardia explain:
how giredestrant is different from the two other available SERDs
if giredestrant could be combined with a CDK4/6 inhibitor
giredestrant side effects
what the results mean for people diagnosed with early-stage hormone receptor-positive breast cancer
More from Breastcancer.org Podcast
Actress Miranda McKeon was diagnosed with stage III breast cancer at age 19, just as she was starting her sophomore year of college. She talks about her experiences with diagnosis and treatment, as well as how she balanced presenting herself to her peers in a way that felt authentic when she was living an experience that was completely foreign to her.
Julia Maués didn’t decide to become an advocate, but her passion for patients learning science and scientists learning patient experiences propelled her to talk about her experiences.
Eleonora Teplinsky’s oncology practice has focused on people with breast cancer for more than a decade. Her new book, Beyond the Pink: Navigating Life, Health, and Breast Cancer, explains breast cancer risks, screening, diagnosis, and treatment, as well as topics that may not be discussed by all doctors.
Dr. Luba Perry is the founder and CEO of ReConstruct Bio, where she’s working to develop bioengineered living tissue implants made from a person’s own cells that then integrate with the body as living tissue. The first goal is to develop natural implants for breast reconstruction.
An advocate and communications expert with more than 20 years experience in international corporate marketing, Christina Wilhelm wrote It’s Breast Cancer, Now What? as a manual to help people navigate breast cancer treatment, return-to-work, and long-term follow-up care decisions.